Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masmudur M Rahman

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
Cancers|November 13, 2021
Oncolytic Viruses: Newest Frontier for Cancer ImmunotherapyMasmudur M Rahman, Grant McFadden
Advances in Cancer Research|June 5, 2026
Cancer immunotherapy with oncolytic myxoma virusJacqueline Carmona, Deon Nguyen, Masmudur M Rahman
Vaccine|June 4, 2013
Oncolytic myxoma virus: the path to clinicWinnie M Chan, Masmudur M Rahman, Grant McFadden
Virology|July 29, 2014
Recombinant myxoma virus lacking all poxvirus ankyrin-repeat proteins stimulates multiple cellular anti-viral pathways and exhibits a severe decrease in virulenceStephanie A Lamb, Masmudur M Rahman, Grant McFadden
Seminars in Immunopathology|August 25, 2007
Strategies that modulate inflammasomes: insights from host-pathogen interactionsJames B Johnston, Masmudur M Rahman, Grant McFadden
Advances in Virus Research|July 1, 2008
Poxvirus host range genesSteven J Werden, Masmudur M Rahman, Grant McFadden
Advances in Experimental Medicine and Biology|January 9, 2010
Viral TNF inhibitors as potential therapeuticsMasmudur M Rahman, Alexandra R Lucas, Grant McFadden
Viruses|November 25, 2023
Tumor Tropism of DNA Viruses for Oncolytic VirotherapyJunior A Enow, Hummad I Sheikh, Masmudur M Rahman
Recent Patents on DNA & Gene Sequences|May 3, 2011
Tumor necrosis factor inhibitors from poxviruses with an emphasis on tanapoxvirus-2L proteinDavid Jeng, Masmudur M Rahman, Grant McFadden, et al.
The Journal of Biological Chemistry|June 20, 2006
Variation in ligand binding specificities of a novel class of poxvirus-encoded tumor necrosis factor-binding proteinMasmudur M Rahman, John W Barrett, Peter Brouckaert, et al.
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Cancers|November 13, 2021
Oncolytic Viruses: Newest Frontier for Cancer ImmunotherapyMasmudur M Rahman, Grant McFadden
Advances in Cancer Research|June 5, 2026
Cancer immunotherapy with oncolytic myxoma virusJacqueline Carmona, Deon Nguyen, Masmudur M Rahman
Vaccine|June 4, 2013
Oncolytic myxoma virus: the path to clinicWinnie M Chan, Masmudur M Rahman, Grant McFadden
Virology|July 29, 2014
Recombinant myxoma virus lacking all poxvirus ankyrin-repeat proteins stimulates multiple cellular anti-viral pathways and exhibits a severe decrease in virulenceStephanie A Lamb, Masmudur M Rahman, Grant McFadden
Seminars in Immunopathology|August 25, 2007
Strategies that modulate inflammasomes: insights from host-pathogen interactionsJames B Johnston, Masmudur M Rahman, Grant McFadden
Advances in Virus Research|July 1, 2008
Poxvirus host range genesSteven J Werden, Masmudur M Rahman, Grant McFadden
Advances in Experimental Medicine and Biology|January 9, 2010
Viral TNF inhibitors as potential therapeuticsMasmudur M Rahman, Alexandra R Lucas, Grant McFadden
Viruses|November 25, 2023
Tumor Tropism of DNA Viruses for Oncolytic VirotherapyJunior A Enow, Hummad I Sheikh, Masmudur M Rahman
Recent Patents on DNA & Gene Sequences|May 3, 2011
Tumor necrosis factor inhibitors from poxviruses with an emphasis on tanapoxvirus-2L proteinDavid Jeng, Masmudur M Rahman, Grant McFadden, et al.
The Journal of Biological Chemistry|June 20, 2006
Variation in ligand binding specificities of a novel class of poxvirus-encoded tumor necrosis factor-binding proteinMasmudur M Rahman, John W Barrett, Peter Brouckaert, et al.
Pageof 9